{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:12:42Z","timestamp":1775002362898,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106752","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:34:20Z","timestamp":1757781260000},"page":"106752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical and epidemiological characteristics of late-onset neuromyelitis optica at a tertiary care hospital in Central America"],"prefix":"10.1016","volume":"103","author":[{"given":"Pinilla","family":"Lizeth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1enz","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodriguez","family":"Rainier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Williams","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106752_bib0006","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017"},{"key":"10.1016\/j.msard.2025.106752_bib0001","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis","volume":"271","author":"Arnett","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106752_bib0023","article-title":"Rituximab for the treatment of neuromyelitis optica spectrum disorder. Ottawa (ON): Canadian agency for drugs and technologies in health","author":"Banerjee","year":"2021","journal-title":"Ott. (ON): Can. Agency Drugs Technol. Health;"},{"key":"10.1016\/j.msard.2025.106752_bib0024","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol., Front. Media S.A."},{"key":"10.1016\/j.msard.2025.106752_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102515","article-title":"Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder","volume":"46","author":"Cai","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106752_bib0020","first-page":"259","article-title":"Neuromyelitis optica: clinical and therapeutic update","volume":"5","author":"Carnero Contentti","year":"2013","journal-title":"Neurol. Argent., Ed. Doyma S.L."},{"issue":"5","key":"10.1016\/j.msard.2025.106752_bib0014","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2025.106752_bib0002","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40120-019-0143-2","article-title":"Late onset of neuromyelitis optica spectrum disorders","volume":"8","author":"Fragoso","year":"2019","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.msard.2025.106752_bib0021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/neurolint14010023","article-title":"Neuromyelitis optica spectrum disorder in Central America and the Caribbean: a multinational clinical characterization study","volume":"14","author":"Gracia","year":"2022","journal-title":"Neurol. Int."},{"key":"10.1016\/j.msard.2025.106752_bib0004","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol., Front. Media S.A."},{"key":"10.1016\/j.msard.2025.106752_bib0011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"22","key":"10.1016\/j.msard.2025.106752_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2025.106752_bib0010","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2025.106752_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis Optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106752_bib0022","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WCO.0000000000000455","article-title":"Neuromyelitis optica and neuromyelitis optica spectrum disorders","volume":"30","author":"Marignier","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106752_bib0007","first-page":"60","article-title":"Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018","author":"Monsalve Mu\u00f1oz","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106752_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.33588\/rn.7411.2021498","article-title":"Predictores de discapacidad en una cohorte con espectro de neuromielitis \u00f3ptica","volume":"74","author":"Mu\u00f1oz Osorio","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106752_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120039","article-title":"Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population","volume":"431","author":"Papathanasiou","year":"2021","journal-title":"J. Neurol. Sci"},{"issue":"2","key":"10.1016\/j.msard.2025.106752_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2025.106752_bib0019","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106752_bib0018","first-page":"22","article-title":"Epidemiology of neuromyelitis optica spectrum. New and old challenges","volume":"74","author":"Sep\u00falveda","year":"2022","journal-title":"Rev. Neurol., Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106752_bib0017","article-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol.(R) neuroimmunol. neuroinflammation"},{"issue":"4","key":"10.1016\/j.msard.2025.106752_bib0013","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ene.15239","article-title":"Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies","volume":"29","author":"Wang","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106752_bib0003","author":"Wingerchuk"},{"key":"10.1016\/j.msard.2025.106752_bib0012","article-title":"Relatively early and late-onset neuromyelitis Optica spectrum disorder in Central China","volume":"13","author":"Yu","year":"2022","journal-title":"Clin. Charact. Progn. Features, Front Neurol."},{"key":"10.1016\/j.msard.2025.106752_bib0015","article-title":"Relatively early and late-onset neuromyelitis optica spectrum disorder in Central China","volume":"13","author":"Yu","year":"2022","journal-title":"Clin. Charact. Progn. Features, Front Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:16:28Z","timestamp":1774998988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"alternative-id":["S2211034825004948"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106752","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and epidemiological characteristics of late-onset neuromyelitis optica at a tertiary care hospital in Central America","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106752"}}